Monday, October 3, 2022


Biotechnology News Magazine

Bart Filius Is Appointed President and COO of Galapagos

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Bart Filius joined Galapagos in 2014 as Chief Financial Officer and subsequently took on the responsibility as COO in 2017.

During these years, Bart managed the substantial growth of the company, successfully conducted the Nasdaq IPO, and played a leading role in the negotiations for the R&D partnership with Gilead. (Note: Going forward, CEO Onno van de Stolpe will maintain oversight of the research and development activities, while Bart Filius will take responsibility for business development, commercial strategy, finance, human resources, and other business operations.).

Prior to joining Galapagos, Bart spent 13 years at Sanofi, where he had leadership roles of increasing responsibility in finance, country management and M&A. In his early career, Bart was a strategy consultant at Arthur D. Little. Bart holds an MBA from INSEAD.

Commenting on the promotion, CEO Onno van de Stolpe said, “I’m delighted that Bart will take up this new role. He has been instrumental in transforming Galapagos into a fully integrated biotech, and he has proven that he has outstanding strategic vision, business acumen, and leadership skills. Going forward, I want to give my full attention to research and development and our strategy to develop first-in-class medicines based on the discovery of novel targets.”

Bart Filius added, “I’m highly energized by the opportunity to lead Galapagos into the future, together with Onno and the Management Board. We are in the midst of launching our first commercial product and are preparing for future indications. Galapagos is very keen to broaden its portfolio through smart business development and has the financial resources to do so. To achieve our goals, our business operations need to run smoothly. I look forward with confidence to working on these 3 priorities with the talented team of people that we have on board. These are challenging but exciting times for Galapagos.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine